kENUP Foundation: Vaccine Skepticism in Germany Multiplies With Novel COVID Vaccines
The first representative study of COVID-19 vaccine skeptics, conducted by kENUP Foundation, the Swiss Academies of Arts and Sciences and the EIB Institute, identified the socioeconomic and consumer behavior profile, as well as the dominant values and positions of COVID-19 vaccines skeptics and examined potential strategies to increase willingness to get a COVID-19 vaccine in that cohort.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005455/en/
Most over- and underrepresented characteristics of vaccines skeptics (Graphic: kENUP Foundation)
Overall, 19.6% of the German population make up the COVID-19 vaccine skeptic group, those unlikely or very unlikely to take the jab once offered to them. Almost 84.2% of that group were not opposed to vaccines before the corona crisis. This means that 13.7 million new skeptics are contributing to the high COVID-19 anti-vaccine sentiment.
COVID-19 vaccine skepticism is mainly driven by the fear of long-term damage (66.0%), the fast approval process (54.7%) and fear of adverse health effects (53.0%). It correlates with corona virus denial: 21.7% of vaccine skeptics and 36.8% of long-term anti-vaccinationists disagree that COVID-19 causes serious health problems. Denial of the virus infecting many people worldwide is 21.8% and 40%, respectively for new skeptics and long-term anti-vaccinationists.
While 69.3% of all vaccine skeptics could be convinced to take the COVID-19 vaccine through factual assurances, 69.4% of long-term anti-vaccinationists state that nothing would convince them. On the assurances needed for attitudinal change within the overall cohort, exclusion of long-term damage (52.0%), proven effectiveness (40.8%) and the evidence that genes are not changed (32.0%) top the list. Also, neither celebrity endorsement nor prospects of long-distance travel are convincing skeptics to be vaccinated. Vaccine skeptics seem to have more trust in vaccines originating from Germany, the United States, and the United Kingdom. Vaccines from Russia, China and especially India have a low chance of approval by skeptics.
A prevailing lack of life meaning and political participation defines the cohort of vaccine skeptics: 89.2% feel that they have no influence over politics. Of the long-term anti-vaccinationists, 35.2% express existential fears and financial worries, with life lacking any perspective for 35.6% of them. In terms of political affiliation, the anti-vaccination group is predominantly AfD-leaning (43.0%, far-right), with support of FDP (liberal) and Die Linke (left) also over-represented, while affinity to SPD (centre-left), CDU/CSU (centre-right) and Die Grünen (green) remains significantly underrepresented. Anti-vaccination sentiments are much higher in people of non-Christian religions.
The full report and more information can be found at https://www.kenup.eu/press and https://www.covidx.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005455/en/
Contact information
Press contact
kENUP: Tobias Mac-Lean, maclean@kenup.eu, https://www.kenup.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 19:00:00 EET | Press release
LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams can test smarter, accelerate release cycles, and achieve faster time-to-market at scale. Founded in 2017, LambdaTest is headquartered in San Franc
GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 17:11:00 EET | Press release
Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and success of Acrelec, serving as Co-Founder and Co-C
Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 15:00:00 EET | Press release
Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, tax, HR, and payroll in a single unified platform. Accelerating Cegid’s European growth strategy by serving more than one million SMBs, and 15,000 accountants Shine brings to Cegid more than 400,000 SMB customers, a strong brand, and a highly scalable
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne. “That pace reflects both the strength of the data and the urgency of the need for patients with R/R MCL. With rapid, deep, and durable responses and a manageable safety profile, sonrotoclax is emerging as a potential best-in-class BCL2 inhibitor, alongside our two other transformative hematology assets – BTK inhibitor BRUKINSA, and investigational BTK degrader BGB-16
Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 12:15:00 EET | Press release
Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championship golf course located in Wellington, Florida – a global icon of equestrian sport. This investment marks Modon’s first direct investment in an equestrian led development in the United States, complementing its existing global portfolio, and reinforcing its strategy to partner with leading international organisations in expanding its presence across ultra-luxury destin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
